ENOV logo

ENOVIS CORP

ENOVNYSE
πŸ† #1830 by market capEarnings Nov 5US Equity
$24.60β–² $0.37 (+1.49%)
πŸŒ™ After hours$24.60β–² 0.00%Regular close Β· extended-hours price shown
1hβ€”
24hβ–² 1.5%
7dβ–Ό 18.4%
14dβ–Ό 18.6%
30dβ–Ό 6.4%
1yβ–Ό 14.4%
🏦Market Cap
$1.42B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+6.7%
Slowing
πŸ“ŠGross Margin
57.4%
Healthy
πŸ’΅FCF Margin
2.8%
Thin
βš–οΈP/S Ratio
0.6x
Cheap
Otter Score
49
Weak

Trading Snapshot

Day Range
$24.40 – $25.02
52-Week Range
$19.14 – $34.28
Volume
$6.13B
Avg Volume
$5.84B
Shares Outstanding
57.6M
Next Earnings
Oct 6, 2026

Fundamentals Snapshot

Annual Revenue
$2.25B
Last Q Revenue
$583M
P/E Ratio
-1.3
P/S Ratio
0.6x
EPS (TTM)
$-19.13
Dividend Yield
0.00%

Why Investors Own ENOV

  • βœ“High-growth profile β€” revenue up +51.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 57% gross margin and 7% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2.25Bβ–² +54.7% YoY
Gross Margin (TTM)
56.9%β–Ό βˆ’0.3% YoY
Operating Income (TTM)
$803Mβ–² +54.7% YoY
Free Cash Flow (TTM)
$146Mβ–² +54.7% YoY

About ENOVIS CORP

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionalsβ€”including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainersβ€”who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
49/100

Analyst Ratings

β“˜
Consensus
Buy
19 analysts
Strong Buy6
Buy11
Hold2
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

πŸš€
BenzingaΒ·4d ago

Wells Fargo Maintains Overweight on Enovis, Lowers Price Target to $39

Wells Fargo analyst Larry Biegelsen maintains Enovis (NYSE:ENOV) with a Overweight and lowers the price target from $40 to $39.

SeekingAlphaΒ·5d ago

Enovis Corporation 2026 Q2 - Results - Earnings Call Presentation

2026-08-07. The following slide deck was published by Enovis Corporation in conjunction with their 2026 Q2 earnings call.

SeekingAlphaΒ·5d ago

Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript

Enovis Corporation (ENOV) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsKyle Rose - Vice President of Investor RelationsDamien...

πŸš€
BenzingaΒ·5d ago

BTIG Maintains Buy on Enovis, Raises Price Target to $40

BTIG analyst Ryan Zimmerman maintains Enovis (NYSE:ENOV) with a Buy and raises the price target from $39 to $40.

πŸ›°οΈ
BenzingaΒ·5d ago

Enovis Q2 Adj. EPS $0.90 Beats $0.85 Estimate, Sales $582.782M Beat $582.542M Estimate

Enovis (NYSE:ENOV) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.85 by 5.88 percent. This is a 13.92 percent increase over earnings of $0.79 per share from the same

🌌
BenzingaΒ·5d ago

Enovis Affirms FY2026 Adj EPS Guidance of $3.52-$3.73 vs $3.65 Est; Affirms FY2026 Sales Guidance of $2.310B-$2.370B vs $2.345B Est

Enovis (NYSE:ENOV) affirms FY2026 Adj EPS guidance from $3.52-$3.73 to $3.52-$3.73 vs $3.65 analyst estimate. Affirms FY2026 sales outlook from $2.310 billion-$2.370 billion to $2.310 billion-$2.370 billion vs $2.345